RTW Biotech Opp. - Director Declaration
03/10/2023 16:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231003:nRSC5644Oa&default-theme=true RNS Number : 5644O RTW Biotech Opportunities Ltd 03 October 2023 LEI: 549300Q7EXQQH6KF7Z84 03 October 2023 RTW Biotech Opportunities Ltd (the "Company") Director Declaration In accordance with Listing Rule 9.6.14(2), the Company advises that Paul Le Page, a non-executive director of the Company, has been appointed as an independent non-executive director of NextEnergy Solar Fund Limited, a LSE listed FTSE 250 company, with effect from 03 October 2023. In addition, Paul Le Page has recently resigned from Bluefield Solar Investment Fund Limited, an LSE listed FTSE 250 company. Paul's role at NextEnergy Solar Fund Limited is not expected to impact his ability to allocate sufficient time to the Company to discharge his responsibilities effectively. For Further Information: RTW Investments, LP +44 20 7959 6361 Woody Stileman, Managing Director Krisha McCune, Director, Client Service Buchanan +44 20 7466 5107 Charles Ryland Henry Wilson George Beale Numis +44 20 7260 1000 Freddie Barnfield Nathan Brown Euan Brown BofA Securities +44 20 7628 1000 Edward Peel Kieran Millar Cadarn Capital +44 73 6888 3211 David Harris Elysium Fund Management Limited +44 (0) 14 8181 0100 Joanna Duquemin Nicolle, Chief Executive Officer Sadie Morrison, Managing Director Morgan Stanley Fund Services USA LLC +1 914 225 8885 About RTW Biotech Opportunities Ltd: RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies. Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd (https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/) for more information. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END RDNBXBDGGSGDGXX